PPARgamma modulators
AssigneeTularik Inc.
InventorsFabienne De la Brouse-Elwood, Jin-Long Chen, Timothy D. Cushing, John A. Flygare, Jonathan B. Houze, Juan C. Jaen, Lawrence R. McGee, Shi-Chang Miao, Steven Marc Rubenstein, Patrick C. Kearney
Life of this patent
Estimating the term…
Abstract
Modulators of PPARγ activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
Claims84
A compound having the formula:
- 57
- wherein
- Ar1 is an aryl group;
- X is a divalent linkage selected from the group consisting of (C1-C6)alkylene, (C1-C6)alkylenoxy, —O—, —C(O)—, —N(R11)-, —N(R11)C(O)—, —S(O)k— and a single bond,
- wherein
- R11 is a member selected from the group consisting of hydrogen, alkyl, heteroalkyl and arylalkyl;
- and the subscript k is an integer of from 0 to 2;
- Y is a divalent linkage selected from the group consisting of alkylene, —O—, —C(O)—, —N(R12)-S(O)m—, N(R12)-S(O)m—N(R13)-, —N(R12)C(O)—, —S(O)n— and a single bond,
- wherein
- R12 and R13 are members independently selected from the group consisting of hydrogen, alkyl, heteroalkyl and arylalkyl;
- and the subscripts m and n are independently integers of from 0 to 2;
- R1 is a member selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl, arylalkyl, —C(O)R14, —CO2R14, —C(O)NR15R16, —S(O)P-R14 —S(O)q—NR15R16, —O—C(O)—OR17, —O—C(O)-R′, —O—C(O)-NR15R16, —N(R14)-C(O)—NR15R16, —N(R14)-C(O)-R17 and —N(R14)-C(O)—OR17;
- wherein
- R14 is a member selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl and arylalkyl;
- R15 and R16 are members independently selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl, and arylalkyl, or taken together with the nitrogen to which each is attached form a 5-, 6- or 7-membered ring;
- R17 is a member selected from the group consisting of alkyl, heteroalkyl,aryl and arylalkyl;
- the subscript p is an integer of from 0 to 3;
- and
- the subscript q is an integer of from 1 to 2;
- and
- R2 is a member selected from the group consisting of alkyl, heteroalkyl, aryl and arylalkyl
- with the proviso that when Ar1-X- is 5-chloro-3-pyridyloxy, R1 is carboethoxy and Y is —NHSO2—, and the groups Ar1-X-, R1 and -Y-R2 occupy positions at carbons 2, 1 and 5 of the benzene ring, respectively, then R2 is other than 4-tolyl or 2,4-dichloro-5-methylphenyl.
A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound having the formula:
- 69
- wherein
- Ar1 is an aryl group;
- X is a divalent linkage selected from the group consisting of (C1-C6)alkylene, (C1-C6)alkylenoxy, —O—, —C(O)—, —N(R11)-, —N(R11)C(O)—, —S(O)k— and a single bond,
- wherein
- R11 is a member selected from the group consisting of hydrogen, alkyl, heteroalkyl and arylalkyl;
- and the subscript k is an integer of from 0 to 2;
- Y is a divalent linkage selected from the group consisting of alkylene, —O—, —C(O)—, —N(R12)-S(O)m—, —N(R12)—S(O)m—N(R13)-, —N(R12)C(O)—, —S(O)n— and a single bond,
- wherein
- R12 and R13 are members independently selected from the group consisting of hydrogen, alkyl, heteroalkyl and arylalkyl;
- and the subscripts m and n are independently integers of from 0 to 2;
- R1 is a member selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl, arylalkyl, —C(O)R14, —CO2R14, —C(O)NR15R16, S(O)p-R14, —S(O)q—NR15R16, —O—C(O)—OR17, —O—C(O)-R17, —C(O)—NR15R16, —N(R14)-C(O)—NR15R16, —N(R4)-C(O)-R17 and —N(R14)-C(O)—OR17;
- wherein
- R14 is a member selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl and arylalkyl;
- R15 and R16 are members independently selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl, and arylalkyl, or taken together with the nitrogen to which each is attached form a 5-, 6- or 7-membered ring;
- R17 is a member selected from the group consisting of alkyl, heteroalkyl,aryl and arylalkyl;
- the subscript p is an integer of from 0 to 3;
- and
- the subscript q is an integer of from 1 to 2;
- and
- R2 is a member selected from the group consisting of alkyl, heteroalkyl, aryl and arylalkyl.
A method for modulating conditions associated with metabolic or inflammatory disorders in a host, said method comprising administering to said host an efficacious amount of a compound having the formula:
- 82
- wherein
- Ar1 is an aryl group;
- X is a divalent linkage selected from the group consisting of (C1-C6)alkylene, (C1-C6)alkylenoxy, —O—, —C(O)—, —N(R11)-, —N(R11)C(O)—, —S(O)k— and a single bond,
- wherein
- R11 is a member selected from the group consisting of hydrogen, alkyl, heteroalkyl and arylalkyl;
- and the subscript k is an integer of from 0 to 2;
- Y is a divalent linkage selected from the group consisting of alkylene, —O—, —C(O)—, —N(R12)-S(O)m—, N(R12)-S(O)m—N(R13)-, —N(R12)C(O)—, —S(O)n— and a single bond,
- wherein
- R12 and R13 are members independently selected from the group consisting of hydrogen, alkyl, heteroalkyl and arylalkyl;
- and the subscripts m and n are independently integers of from 0 to 2;
- R1 is a member selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl, arylalkyl, —C(O)R14, —CO2R14, —C(O)NR15R16, —S(O)p-R14, —S(O)q—NR15R16, —O—C(O)—OR17, —O—C(O)-R17, —O—C(O)—NR15R16, —N(R14)-C(O)—NR15R16, —N(R14)-C(O)-R17 and —N(R14)-C(O)—OR17;
- wherein
- R14 is a member selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl and arylalkyl;
- R15 and R16 are members independently selected from the group consisting of hydrogen, alkyl, heteroalkyl, aryl, and arylalkyl, or taken together with the nitrogen to which each is attached form a 5-, 6- or 7-membered ring;
- R17 is a member selected from the group consisting of alkyl, heteroalkyl,aryl and arylalkyl;
- the subscript p is an integer of from 0 to 3;
- and
- the subscript q is an integer of from 1 to 2;
- and
- R2 is a member selected from the group consisting of alkyl, heteroalkyl, aryl and arylalkyl.
Dependencies are inferred from the claim text.